Framework for Future Analysis of Immune Response to Immunotherapy in Liver Cancer – NCI Center for Cancer Research
NCI Center for Cancer Research shared a post on LinkedIn about a paper by Yuta Myojin et al. published in Gut:
“NIH researchers of the National Cancer Institute conducted a clinical trial to study immune responses in hepatocellular carcinoma (liver cancer) patients treated with tremelimumab and durvalumab, a standard treatment option for the disease. They analyzed tumor tissue and uncovered the critical role of Treg, a type of immune cell, in determining the effectiveness of the drug treatment.
This study provides a framework for future analysis into how the immune system responds to immunotherapy in liver cancer. Their findings on Treg can also help physicians determine which patients can benefit the most from this treatment regimen.
Image: List of samples of each patient used in the correlative study from the NCT0282154 cohort.”
Title: Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
Authors: Yuta Myojin, Sepideh Babaei, Rajiv Trehan, Christoph Hoffman, Noemi Kedei, Benjamin Ruf, Mohamed-Reda Benmebarek, Kylynda C. Bauer, Patrick Huang, Chi Ma, Cecilia Monge, Changqing Xie, Donna Hrones, Austin G. Duffy, Paul Armstrong, Lorenz Kocheise, Fiona Desmond, Jemma Buchalter, Marie Galligan, Colin Cantwell, Ronan Ryan, Jeff McCann, Michele Bourke, Ross Mac Nicholas, Ray McDermott, Joy Awosika, Maggie Cam, Rosanna Krebs, Anuradha Budhu, Mahler Revsine, William D. Figg, David E. Kleiner, Bernadette Redd, Bradford J. Wood, Xin Wei Wang, Firouzeh Korangy, Manfred Claassen, Tim F. Greten.
You can read the Full Article in Gut.
More posts featuring NCI Center for Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023